Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Meta-analysis of phase III trials
10.1016/j.lungcan.2011.04.008
Saved in:
Main Authors: | Ku, G.Y., Haaland, B.A., de Lima Lopes, G. |
---|---|
Other Authors: | DUKE-NUS GRADUATE MEDICAL SCHOOL S'PORE |
Format: | Article |
Published: |
2016
|
Subjects: | |
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/124650 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung
by: De Lima Lopes Jr., G., et al.
Published: (2016) -
Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer
by: Wong, A.S., et al.
Published: (2014) -
EGFR S1166 phosphorylation induced by a combination of EGF and gefitinib has a potentially negative impact on lung cancer cell growth
by: Assiddiq, B.F., et al.
Published: (2014) -
Chemotherapy in non-small cell lung cancer: opportunities for advancement
by: Akhtari, M, et al.
Published: (2020) -
Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC
by: Tan, Eng-Huat, et al.
Published: (2022)